Cardiff Oncology (CRDF) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pelthos Therapeutics (PTHS) has outperformed Cardiff Oncology (CRDF) over the past year, losing 18.0% versus a loss of 54.6%. Cardiff Oncology is the larger company by market cap ($84.0 million vs $78.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | PTHS |
|---|---|---|
| Share price | $1.08 | $20.50 |
| Market cap | $84.02M | $78.48M |
| 1-day change | +1.89% | 0.00% |
| YTD return | -61.57% | -33.87% |
| 1-year return | -54.62% | -18.00% |
| 5-year return | -83.13% | — |
| EPS (TTM) | $-0.60 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $37.50 |
| 52-week low | $0.76 | $18.19 |
| Distance from 52-week high | -67.37% | -45.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +437.96% | +159.22% |
| Average volume | 1.04M | 60.31K |
| Shares outstanding | 77.80M | 3.83M |
| Employees | 30 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTHS has outperformed CRDF by 36.6 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
CRDF vs PTHS FAQ
Which is bigger, Cardiff Oncology or Pelthos Therapeutics?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $84.02M compared with $78.48M for Pelthos Therapeutics (PTHS).
Which stock has performed better over the past year, CRDF or PTHS?
PTHS returned -18.00% over the past 12 months, compared with -54.62% for CRDF (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.